Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc. on March 3, 2025, covering events that occurred on February 28, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Atlanta, Georgia. The filing addresses corporate governance amendments and the establishment of a new class of preferred stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate actions rather than financial performance results.
Material Changes and Corporate Actions
- Bylaws Amendment: The Board adopted the First Amendment to the Amended and Restated Bylaws, effective immediately. The amendment reduced the quorum requirement for stockholder meetings from a majority (50% + 1) of outstanding capital stock to 35% of outstanding capital stock entitled to vote.
- Series C Preferred Stock: The Company filed a Certificate of Designations to establish the Series C Convertible Preferred Stock. This follows a Securities Purchase & Exchange Agreement with a sophisticated investor involving:
- Exchange of 97.7511 shares of Series A Convertible Preferred Stock for an equal number of Series C shares.
- Sale of up to 500 shares of Series C Preferred Stock to the investor.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the standard incorporation by reference of the full text of the Bylaws Amendment and Certificate of Designations. The Company stated the Bylaws amendment was determined to be in the best interests of the Company and its stockholders.
Key Facts for Investor Verification
- Verify the specific terms, voting rights, and conversion features of the newly issued Series C Convertible Preferred Stock in Exhibit 3.2.
- Confirm the impact of the reduced 35% quorum requirement on future stockholder meeting dynamics and potential governance decisions.
- Review the full text of the Securities Purchase & Exchange Agreement referenced in the prior February 28, 2025 filing to understand the total capital raised and dilution effects.
- Check subsequent filings for any financial impact resulting from the issuance of the Series C Preferred Stock.